ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3  months

The objective of this analysis of the ongoing ETNA-VTE Europe study was to assess the real-world benefits and risks of edoxaban during the first 3  months of treatment, the highest risk period for further VTE events.

Source: Thrombosis Research - September 10, 2020 Category: Hematology Authors: Giancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, Sean Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jimenez, Bernd Br üggenjürgen, Pierre Levy, Petra Laeis, Eva-Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Marius Constantin Manu, Paul- Tags: Full Length Article Source Type: research